Why the study?
Does ECG gated P-31 MRS detect differences in myocardial high-energy phosphate metabolism between patients with cardiomyopathies and normal subjects?
Does ECG gated P-31 MRS detect differences in myocardial high-energy phosphate metabolism between patients with cardiomyopathies and normal subjects?
Answers are grounded in this paper and cite their sources.
ECG gated P-31 MR spectroscopy can non-invasively identify myocardial metabolic disturbances in patients with hypertrophic cardiomyopathy and specific heart muscle disease.
Nuclear magnetic resonance spectroscopy (MRS) is a new technique for the evaluation of myocardial metabolism. Recently, localized MRS has been clinically available to measure by a non-invasive method the relative concentrations of the high-energy phosphate metabolites in the myocardium. We performed ECG gated P-31 MRS using ISIS (image-selected in vivo spectroscopy) in 15 normal volunteers, 12 patients with hypertrophic cardiomyopathy, 12 with left ventricular hypertrophy, 6 with dilated cardiomyopathy and 11 with specific heart muscle disease. Myocardial peak height ratios of PCr/gamma-ATP, Pi/gamma-ATP and PCr/Pi were measured. Myocardial P-31 MRS demonstrated a significant decrease in the ratio PCr/ATP in patients with hypertrophic cardiomyopathy and specific heart muscle disease as compared with normal subjects, indicating myocardial metabolic disturbance in these patients. The ratio of PCr/ATP in patients with dilated cardiomyopathy did not differ significantly from that of normal subjects. However, exercise MRS revealed a marked decrease of PCr peak in an asymptomatic patient with dilated cardiomyopathy, which may indicate a latent metabolic disturbance in the myocardium of dilated cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Masuda et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: